<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948259</url>
  </required_header>
  <id_info>
    <org_study_id>NP031112-08B03 (CR080901)</org_study_id>
    <nct_id>NCT00948259</nct_id>
  </id_info>
  <brief_title>Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease</brief_title>
  <official_title>Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noscira SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noscira SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112
      are safe and tolerated in patients with Alzheimer´s disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rates and severity of clinical adverse events and lab abnormalities for each dose level and placebo</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment with four doses of NP031112 on cognition and depressive mood</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>NP031112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP031112</intervention_name>
    <description>unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)</description>
    <arm_group_label>NP031112</arm_group_label>
    <other_name>tideglusib</other_name>
    <other_name>NP12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women (non-childbearing potential) with a diagnosis of probable Alzheimer's
             disease according to the NINCDS-ADRDA clinical criteria.

          2. Age 60 - 85 years (patients over 85 years could be included after a previous
             assessment by the investigator and in agreement with the sponsor)

          3. MRI or CT-scan assessment within 12 months before baseline corroborating the clinical
             diagnosis (diffuse brain atrophy predominating in medial temporal regions) and
             excluding other potential causes of dementia, especially cerebrovascular lesions (see
             exclusion criteria, number 3).

          4. Mild to moderate stage of Alzheimer's disease according to MMSE 16-26.

          5. Modified Hachinski ischemic score equal to or below 4.

          6. Geriatric Depression Scale below or equal 7.

          7. Female patients must be either surgically sterilized or at least 1 year postmenopausal
             (confirmed by FSH &gt;20, for women not surgically sterilized).

          8. A caregiver/nurse is available and is living in the same household, or interacts with
             the patient to assure the correct preparation and administration of the study drug to
             the patient.

          9. Patients living at home or old people's home.

         10. General health status acceptable for a participation in a 6 months clinical trial.

         11. Ability to swallow 100 -150 ml of water suspension.

         12. No daily-regular/chronic intake of medications acting on central nervous system,
             immunosuppressants, steroids or non-steroid anti-inflammatory agents except the
             following allowed treatments:

               -  SSRIs as antidepressants if they are administered at a stable and well tolerated
                  dose for two months prior to baseline evaluation

               -  the following drugs at a stable and well tolerated dose to symptomatic treatment
                  of mild behavioral disorder, sleep onset-insomnia or mild depressive mood:

                    -  Risperidon max 1mg/day

                    -  Quetiapin max 25mg/day

                    -  Zolpidem max 10mg in the evening

                    -  Lorazepam max 1mg/day

                    -  Triazolam max 0,25mg/day

                    -  Alprazolam max 1mg/day

                    -  Mirtazapin max 30mg/day

               -  Hydromorphon max 4mg/day

               -  Levodopa max 50mg t.i.d as treatment of an age-associated extrapyramidal syndrome
                  or restless-legs-syndrome

               -  Acetylsalicylic acid max 100mg/day as antiplatelet agent.

               -  Non-steroid anti-rheumatics as concomitant medication taken per request

         13. No history of treatment with Warfarin, Digitoxin or Coumarin (including its
             derivatives) within 1 month prior to baseline. Chronic treatment with heparin s.c. as
             anticoagulant or digoxin for the treatment of heart disease are allowed.

         14. Other drugs metabolized by the CYP3A4 with wide therapeutic window are permitted if
             their dose and regimen are stable and well tolerated for at least 1 month prior to
             baseline.

         15. Stable pharmacological treatment of any other chronic condition for at least one month
             prior to screening.

         16. Treatment with a stable and well tolerated dose of one of the approved
             Acetylcholinesterase-Inhibitors (Donepezil, Galantamine or Rivastigmine) for at least
             2 months prior to baseline evaluations. Dosage of Acetylcholine-esterase inhibitors
             should not be increased during the ongoing study.

         17. No history of treatment with Memantine within 3 months prior to baseline evaluation.
             Patients with a stable and well tolerated dose of Memantine are not allowed to be
             included in the study.

         18. Signed informed consent by patient prior to the initiation of any study specific
             procedure

        Exclusion Criteria:

          1. Failure to perform screening or baseline examinations.

          2. Hospitalization or change of chronic concomitant medication within 1 month prior to
             screening period.

          3. Clinical, laboratory or neuroimaging findings consistent with:

               -  other primary degenerative dementia, (dementia with Lewy bodies, frontotemporal
                  dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc)

               -  other neurodegenerative condition (Parkinson's disease, amyotrophic lateral
                  sclerosis, etc.)

               -  cerebrovascular disease (major infarct, one strategic or multiple lacunar
                  infarcts, extensive white matter lesions)

               -  other central nervous system diseases (severe head trauma, tumors, subdural
                  haematoma or other space occupying processes, etc.)

               -  seizure disorder

               -  other infectious, metabolic or systemic diseases affecting central nervous system
                  (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency,
                  serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.)

          4. A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar
             disorder.

          5. Clinically significant, advanced or unstable disease that may interfere with
             evaluations that may bias the assessment of the clinical or mental status of the
             patient or put the patient at special risk, such as:

               -  chronic liver disease, liver function test (LFT) abnormalities or other signs of
                  hepatic insufficiency

               -  respiratory insufficiency

               -  renal insufficiency (serum creatinine &gt;2mg/dl and creatinine clearance ≤ 60
                  mL/min according to Cockgroft-Gault formula).

               -  heart disease (myocardial infarction, unstable angina, heart failure,
                  cardiomyopathy within 6 months before screening)

               -  bradycardia (heart beat &lt;50/min.) or tachycardia (heart beat &gt;95/min.)

               -  hypertension or hypotension if not well controlled or unstable for &gt; 2 months
                  prior to baseline.

               -  AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus
                  node dysfunction or prolonged QTcB-interval (males &gt;450 and females &gt;470 msec)

               -  uncontrolled diabetes

               -  malignant tumors within the last 5 years except skin malignancies (other than
                  melanoma) or indolent prostate cancer

               -  metastases

          6. Disability that may prevent the subject from completing all study requirements (e.g.,
             blindness, deafness, severe language difficulty, etc.)

          7. Women who are fertile and of child bearing potential.

          8. Anticoagulant treatment with heparin i.v.

          9. Chronic drug intake of:

               -  drugs metabolized by the CYP3A4 with narrow therapeutic window (i.e. warfarin,
                  digitoxin, …).

               -  antidepressants, benzodiazepines, neuroleptics or sedatives except those defined
                  as allowed in the inclusion criterion number 12

               -  proton-pump inhibitors

               -  antiepileptics

               -  anticholinergics

               -  nootropics

               -  centrally active anti-hypertensive drugs (clonidine, alpha-methyl dopa,
                  guanidine, guanfacine, …)

               -  opioid containing analgesics

               -  non-steroid anti-inflammatory agents (except taken as concomitant medication per
                  request as defined in the inclusion criterion number 12), cortico-steroids or
                  immunosuppressants

               -  memantine, lithium or other inhibitor of GSK3 enzyme

         10. Suspected or known drug or alcohol abuse.

         11. Suspected or known allergy to any components of the study treatments.

         12. Enrolment in another investigational study or intake of investigational drug within
             the previous 3 months.

         13. Any condition which in the opinion of the investigator makes the patient unsuitable
             for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus-Christian Steinwachs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Studienzentrum PD Dr. Steinwachs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Windisch, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>JSW Life Sciences GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmacologische Studiecentrum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>09111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzneimittelforschung Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>0410Y</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum PD Dr. Steinwachs</name>
      <address>
        <city>Nürnberg</city>
        <zip>D- 90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <last_update_submitted>November 10, 2009</last_update_submitted>
  <last_update_submitted_qc>November 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Teodoro del Ser /Medical Director</name_title>
    <organization>Noscira SA</organization>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>GSK inhibitor</keyword>
  <keyword>Alzheimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

